Abstract
We described chemical inhibitors of Mos1 transposition. Some were already known to affect a related prokaryotic transposase (Tn5) or HIV-1 integrase, whereas the other were new compounds in this field. The new compounds were all organized around a bis-(heteroaryl)maleimides scaffold. Their mechanism of action depended on the chemical substitutions on the scaffold. The cross-activity, between HIV-1 integrase and Mos1 transposase, of the new group of inhibitors showed that Mos1 transposase could constitute an excellent surrogate HIV-1 inhibitor screen.
Keywords: Heterocyclic chemistry, maleimides, transposon inhibitor, HIV-1 integrase inhibitor, mariner inhibitor
Mini-Reviews in Medicinal Chemistry
Title: First Mariner Mos1 Transposase Inhibitors (Supplementary Data)
Volume: 9 Issue: 4
Author(s): N. Bouchet, J. Bischerour, S. Germon, J. Guillard, M. Dubernet, M. C. Viaud-Massuard, O. Delelis, V. Ryabinin, Y. Bigot and C. Auge-Gouillou
Affiliation:
Keywords: Heterocyclic chemistry, maleimides, transposon inhibitor, HIV-1 integrase inhibitor, mariner inhibitor
Abstract: We described chemical inhibitors of Mos1 transposition. Some were already known to affect a related prokaryotic transposase (Tn5) or HIV-1 integrase, whereas the other were new compounds in this field. The new compounds were all organized around a bis-(heteroaryl)maleimides scaffold. Their mechanism of action depended on the chemical substitutions on the scaffold. The cross-activity, between HIV-1 integrase and Mos1 transposase, of the new group of inhibitors showed that Mos1 transposase could constitute an excellent surrogate HIV-1 inhibitor screen.
Export Options
About this article
Cite this article as:
Bouchet N., Bischerour J., Germon S., Guillard J., Dubernet M., Viaud-Massuard C. M., Delelis O., Ryabinin V., Bigot Y. and Auge-Gouillou C., First Mariner Mos1 Transposase Inhibitors (Supplementary Data), Mini-Reviews in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/138955709787847912
DOI https://dx.doi.org/10.2174/138955709787847912 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Integrins: Regulators of Tissue Function and Cancer Progression
Current Pharmaceutical Design Immunity to Tumour Antigens
Current Pharmaceutical Design Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Targeted Therapies in the Treatment of Breast Cancer and Localized Sarcomas)
Current Medicinal Chemistry Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
Current Cancer Drug Targets Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology